Premium
GLP‐1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome
Author(s) -
Hellström P. M.,
Näslund E.,
Edholm T.,
Schmidt P. T.,
Kristensen J.,
Theodorsson E.,
Holst J. J.,
Efendic S.
Publication year - 2008
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/j.1365-2982.2007.01079.x
Subject(s) - motility , irritable bowel syndrome , migrating motor complex , medicine , jejunum , gastric emptying , endocrinology , glucagon like peptide 1 , gastrointestinal hormone , glucagon like peptide 2 , gastroenterology , ileum , small intestine , receptor , chemistry , peptide hormone , stomach , biology , peptide , type 2 diabetes , biochemistry , diabetes mellitus , genetics
Glucagon‐like peptide‐1 (GLP‐1) is released after food intake to act as an incretin. GLP‐1 also inhibits gastric emptying and increases satiety. In rats, GLP‐1 inhibits small bowel motility. Our aim was to study the effects of GLP‐1 on gastrointestinal motility in healthy subjects and patients with irritable bowel syndrome (IBS). Antro‐duodeno‐jejunal manometry was carried out during a 4‐h control period with saline, followed by a 4‐h period with intravenous GLP‐1 (healthy: 0.7 and 1.2 pmol kg −1 min −1 ( n = 16); IBS, 1.2 and 2.5 pmol kg −1 min −1 ( n = 14). Plasma was analysed for GLP‐1 and gut hormones, and gut tissue expression of GLP‐1 receptor was studied. In healthy subjects, GLP‐1 0.7 pmol kg −1 min −1 reduced the migrating motor complexes (MMCs) from a median of 2 (range 2–3) to 0.5 (0–2), and motility index from 4.9 ± 0.1 to 4.3 ± 0.3 ln ∑(mmHg*s min −1 ) in jejunum, while GLP‐1 1.2 pmol kg −1 min −1 diminshed MMCs from 2 (2–3) to 1.5 (1–2.5), and motility index from 5.2 ± 0.2 to 4.4 ± 0.2. In IBS patients, GLP‐1 1.2 pmol kg −1 min −1 reduced the MMCs from 2.5 (2–3.5) to 1 (0–1.5) without affecting motility index. At 2.5 pmol kg −1 min −1 GLP‐1 decreased MMCs from 2 (1.5–3) to 1 (0.5–1.5), and motility index from 5.2 ± 0.2 to 4.0 ± 0.5. Motility responses to GLP‐1 were similar in antrum and duodenum. Presence of the GLP‐1 receptor in the gut was verified by reverse transcriptase PCR. In conclusion, the gut peptide GLP‐1 decreases motility in the antro‐duodeno‐jejunal region and inhibits the MMC in healthy subjects and IBS patients.